Recombinant lentivector as a genetic immunization vehicle for antitumor immunity

Yukai He, David H Munn, Louis D. Falo

Research output: Contribution to journalReview article

23 Citations (Scopus)

Abstract

Encouraged by remarkable successes in preventing infectious diseases and by the well-established potential of the immune system for controlling tumor growth, active therapeutic immunization approaches hold great promise for treating malignant tumors. In recent years, engineered recombinant viral vectors have been carefully examined as genetic-immunization vehicles and have been demonstrated to induce potent T-cell-mediated immune responses that can control tumor growth. Very recent efforts suggest that lentivectors possess important advantages over other candidate recombinant viral vectors for genetic immunization. Here, we review the development of recombinant lentivectors and the characteristics of T-cell immune responses elicited by lentivector immunization, including the mechanism of T-cell priming with a focus on the role of skin dendritic cells and potential applications for tumor immunotherapy.

Original languageEnglish (US)
Pages (from-to)913-924
Number of pages12
JournalExpert Review of Vaccines
Volume6
Issue number6
DOIs
StatePublished - Dec 1 2007

Fingerprint

Immunity
Immunization
T-Lymphocytes
Neoplasms
Genetic Vectors
Langerhans Cells
Growth
Immunotherapy
Communicable Diseases
Immune System
Vaccination
Therapeutics

Keywords

  • Dendritic cell subsets
  • Gene delivery
  • Genetic immunization
  • Lentivector (lentiviral vector)
  • Tumor immunotherapy

ASJC Scopus subject areas

  • Immunology
  • Molecular Medicine
  • Pharmacology
  • Drug Discovery

Cite this

Recombinant lentivector as a genetic immunization vehicle for antitumor immunity. / He, Yukai; Munn, David H; Falo, Louis D.

In: Expert Review of Vaccines, Vol. 6, No. 6, 01.12.2007, p. 913-924.

Research output: Contribution to journalReview article

@article{6f6f9924b35047858a6bf7b727589305,
title = "Recombinant lentivector as a genetic immunization vehicle for antitumor immunity",
abstract = "Encouraged by remarkable successes in preventing infectious diseases and by the well-established potential of the immune system for controlling tumor growth, active therapeutic immunization approaches hold great promise for treating malignant tumors. In recent years, engineered recombinant viral vectors have been carefully examined as genetic-immunization vehicles and have been demonstrated to induce potent T-cell-mediated immune responses that can control tumor growth. Very recent efforts suggest that lentivectors possess important advantages over other candidate recombinant viral vectors for genetic immunization. Here, we review the development of recombinant lentivectors and the characteristics of T-cell immune responses elicited by lentivector immunization, including the mechanism of T-cell priming with a focus on the role of skin dendritic cells and potential applications for tumor immunotherapy.",
keywords = "Dendritic cell subsets, Gene delivery, Genetic immunization, Lentivector (lentiviral vector), Tumor immunotherapy",
author = "Yukai He and Munn, {David H} and Falo, {Louis D.}",
year = "2007",
month = "12",
day = "1",
doi = "10.1586/14760584.6.6.913",
language = "English (US)",
volume = "6",
pages = "913--924",
journal = "Expert Review of Vaccines",
issn = "1476-0584",
publisher = "Expert Reviews Ltd.",
number = "6",

}

TY - JOUR

T1 - Recombinant lentivector as a genetic immunization vehicle for antitumor immunity

AU - He, Yukai

AU - Munn, David H

AU - Falo, Louis D.

PY - 2007/12/1

Y1 - 2007/12/1

N2 - Encouraged by remarkable successes in preventing infectious diseases and by the well-established potential of the immune system for controlling tumor growth, active therapeutic immunization approaches hold great promise for treating malignant tumors. In recent years, engineered recombinant viral vectors have been carefully examined as genetic-immunization vehicles and have been demonstrated to induce potent T-cell-mediated immune responses that can control tumor growth. Very recent efforts suggest that lentivectors possess important advantages over other candidate recombinant viral vectors for genetic immunization. Here, we review the development of recombinant lentivectors and the characteristics of T-cell immune responses elicited by lentivector immunization, including the mechanism of T-cell priming with a focus on the role of skin dendritic cells and potential applications for tumor immunotherapy.

AB - Encouraged by remarkable successes in preventing infectious diseases and by the well-established potential of the immune system for controlling tumor growth, active therapeutic immunization approaches hold great promise for treating malignant tumors. In recent years, engineered recombinant viral vectors have been carefully examined as genetic-immunization vehicles and have been demonstrated to induce potent T-cell-mediated immune responses that can control tumor growth. Very recent efforts suggest that lentivectors possess important advantages over other candidate recombinant viral vectors for genetic immunization. Here, we review the development of recombinant lentivectors and the characteristics of T-cell immune responses elicited by lentivector immunization, including the mechanism of T-cell priming with a focus on the role of skin dendritic cells and potential applications for tumor immunotherapy.

KW - Dendritic cell subsets

KW - Gene delivery

KW - Genetic immunization

KW - Lentivector (lentiviral vector)

KW - Tumor immunotherapy

UR - http://www.scopus.com/inward/record.url?scp=37149001171&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=37149001171&partnerID=8YFLogxK

U2 - 10.1586/14760584.6.6.913

DO - 10.1586/14760584.6.6.913

M3 - Review article

C2 - 18377355

AN - SCOPUS:37149001171

VL - 6

SP - 913

EP - 924

JO - Expert Review of Vaccines

JF - Expert Review of Vaccines

SN - 1476-0584

IS - 6

ER -